Eli Lilly's rheumatoid arthritis drug helps in Covid-19 recovery when combined with Remdesivir

Eli Lilly and Co said on Monday its rheumatoid arthritis drug Olumiant helped reduce the time taken to recover from Covid-19 in hospitalized patients in a clinical trial.

The US drugmaker said the drug, in combination with Gilead Sciences Inc's Remdesivir, met the main goal of shortening recovery when compared to Remdesivir alone.